AffaMed Therapeutics and Hanmi Pharmaceutical have entered into a licensing agreement granting AffaMed exclusive rights to develop and commercialize risuteganib in Greater China, according to a press release.
Through the agreement, AffaMed will pay Hanmi $145 million for the right to manufacture, develop and commercialize risuteganib for intermediate dry age-related macular degeneration in mainland China, Hong Kong, Taiwan and Macau, the release said. The payment includes a $6 million upfront licensing fee. Hanmi will also be eligible for royalties depending on net sales.
“We are excited